Pasar al contenido principal

INESTABILIDAD CROMOSOMICA Y PATOFISIOLOGIA DE LAS CELULAS INICIADORAS DE LEUCEMIA EN LA LEUCEMIA LINFOBLASTICA AGUDA PEDIATRICA CON ANEUPLOIDIAS

PID2022-142966OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

  • Guerrero Murillo, Mercedes
  • Marchese, Domenica, 1986-
  • Heyn, Holger
  • Menéndez, Pablo
The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell omics to interrogate cellular dynamics of non-transduced (CARneg) and transduced (CARpos) T cells, in the infusion product (IP) and at the CAR-T cell expansion peak in five B cell acute lymphoblastic leukemia (B-ALL) patients treated with CD19CAR-T cells (varni-cel). We identify significant differences in cellular dynamics in response to therapy. CARpos T cells at IP of complete response patients exhibit a significantly higher CD4:CD8 ratio, validated in a larger cohort B-ALL patients (n = 47). Conversely, at the expansion peak, there is a clonal expansion of CD8+ effector memory and cytotoxic T cells. Cytotoxic CARpos γδ-T cells expansion correlates with treatment efficacy validated in a cohort of B-ALL (n = 18) and diffuse large B cell lymphoma (DLBCL) patients (n = 58). Our data provide insights into the complexity of T cell responses following CAR-T cell therapy and suggest drivers of immunotherapy response., Research in P.M./C.B. laboratory was supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665), H2020 (101057250-CANCERNA), the Fight Kids Cancer Foundation (Cure2MLL project), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/10.13039/501100011033; FEDER Funds; CPP2021-008508, CPP2021-008676, and CPP2022-009759 funded by MICIU/AEI/10.13039/501100011033; and the European Union NextGenerationEU/PRTR), Ayudas Merck de Investigación from Health Merck Foundation, the Spanish Association Against Cancer (AECC, PRYGN234975MENE), and the ISCIII-RICORS within the Next Generation EU program (Plan de Recuperación, Transformación y Resilencia). Additional funding was provided to C.B. by AECC (PRYGN211192BUEN), the Uno Entre Cien Mil Foundation, AIE (MINECO PLE2021-007518), Deutsche José Carreras Leukämie-Stiftung (DJCLS/02R/2023), and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822 and PI24/00763).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness

  • Romero-Moya, Damià
  • Torralba-Sales, Eric
  • Calvo, Cristina
  • Marin-Bejar, Oskar
  • Magallon-Mosella, Maria
  • Distefano, Maximiliano
  • Pera, Joan
  • Castaño, Julio
  • Giorgio, Francesca De
  • González, Jessica
  • Iglesias, Arnau
  • Berenguer Balaguer, Clara
  • Schilling, Marcel
  • Plass, Mireya
  • Pasquali, Lorenzo
  • Català, Albert
  • Molina, Oscar
  • Wlodarski, Marcin W.
  • Bigas Salvans, Anna
  • Giorgetti, Alessandra
GATA2 deficiency is a monogenic transcriptopathy disorder characterized by bone marrow failure (BMF), immunodeficiency, and a high risk of developing myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). Although informative mouse models have been developed, the mechanisms by which GATA2 haploinsufficiency drives disease initiation in humans remain incompletely understood. To address this, we developed a novel humanized model using CRISPR/Cas9 technology to knock-in GATA2-R398W variant in primary cord blood CD34+ cells. Additionally, we introduced specific mutations in SETBP1 and ASXL1 to model distinct premalignant stages of GATA2 deficiency. Through clonal competition and serial transplantation assays, we demonstrated that human CD34 cells harboring the GATA2 mutation exhibit significantly reduced fitness in vivo when competing with wild-type cells. Notably, this fitness disadvantage persists even when GATA2 mutations are combined with oncogenic SETBP1 and ASXL1 drivers, underscoring the dominant, deleterious effect of GATA2 deficiency on hematopoietic stem cell function. Functional in vitro analyses revealed that GATA2-R398W mutation impairs cell proliferation, disrupts cell cycle progression, and induces mitotic defects, which may contribute to hematopoietic stem/progenitor cell loss and impaired self-renewal. Transcriptomic profiles of GATA2-mutant cells revealed that these functional defects are associated with reduced HSC self-renewal capacity and upregulation of the pre-aging phenotype. Our work highlights the feasibility of generating a human GATA2 deficiency model suitable for studying the biological consequences of various GATA2 variants and the generation of a platform to test potential phenotype-rescuing therapeutics., This work was supported by ERA PerMed GATA2-HuMo Funding Mechanism (Spain: Acció Instrumental de SLT011/18/00006 of the Department of Health of the Government of Catalonia), Ministerio de Ciencia e Innovación, which is part of Agencia Estatal de Investigación (AEI), through the Retos Investigación grant, number PID2020-115591RB-I00/ https://doi.org/10.13039/501100011033, and PID2023-146290OB-I00, Fundació La Marató TV3 228/C/2020, Award no. AC23_2/00040 by ISCIII through AES 2023 and within the European Joint Programme Rare Diseases framework, Instituto de Salud Carlos III (ISCIII), "Programa FORTALECE del Ministerio de Ciencia e Innovación", through the project number FORT23/00032 and Finançat per el Departament de Recerca i Universitats de la Generalitat de Catalunya i l'AGAUR (expedient 2021 SGR 00888) to AG. Funding for this project was provided in part by an EHA Research Grant award granted by the European Hematology Association (KOG-202109-01162) and the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 101029927 to OM-B. DR-M was supported by Deutsche José Carreras Leukämie-Stiftung, DJCLS 13 R/2022. JP and MD were supported by Fundació La Marató TV3 228/C/2020. MM-M was supported by the TC030-AND/2022 Predoctoral grant from the Government of Andorra. OM-B is currently supported by the Ramón y Cajal contract (RYC2021-032129-I) funded by AEI/European Social Fund UE. The work in the LP laboratory was supported by "la Caixa" Foundation, LCF-PR-HR24-00150 and by PID2023-151556OB-I00 and CNS2024-154742 funded by MICIU/AEI/10.13039/501100011033 and, as appropriate, by "ESF Investing in your future", by "ESF+" or by "European Union NextGenerationEU/PRTR". The work in AB laboratory was funded by ERA PerMed-Departament de Salut, Generalitat de Catalunya (SLT011/18/00007) and the EJP RD-Instituto de Salud Carlos III (AC23_2/00014). The work of CC and OM was supported by the Spanish Ministry of Economy and Competitiveness/European Union NextGenerationEU (PID2022-142966OB-I00) and the Deutsche José Carreras Leukämie-Stiftung (DJCLS 15 R/2023) to OM. CC is supported by a predoctoral fellowship from the Spanish Ministry of Economy and Competitiveness (PID2022-142966OB-I00). The work of MP was supported by a Ramón y Cajal contract of the Spanish Ministry of Science, Innovation and Universities (Grant: RYC2018-024564-I funded by MICIU/AEI/10.13039/501100011033 and by "El FSE invierte en tu futuro"). The work in the MP laboratory was supported by the project PID2022-139580OB-I00 funded by MICIU/AEI/10.13039/501100011033 and FEDER and by "ERDF A way of making Europe", by the European Union. MWW was supported by Evans MDS DRG grant and American Society of Hematology bridge award. Authors thank the members of the Advanced Optical Microscopy facility from UB (Scientific and Technological Centers, Universitat de Barcelona [CCiTUB]) for their technical support. We thank the CERCA Programme/Generalitat de Catalunya for institutional support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

  • Guerrero-Murillo, Mercedes
  • Rill-Hinarejos, Aina
  • Trincado, Juan L.
  • Bataller, Alex
  • Ortiz-Maldonado, Valentín
  • Benítez-Ribas, Daniel
  • Español-Rego, Marta
  • González-Navarro, Azucena
  • Martínez-Cibrián, Nuria
  • Marchese, Domenica
  • Martín-Martín, Lourdes
  • García-Sancho, Alejandro Martín
  • Rives, Susana
  • Heyn, Holger
  • Juan, Manel
  • Urbano-Ispizúa, Álvaro
  • Delgado, Julio
  • Orfao, Alberto
  • Mereu, Elisabetta
  • Bueno, Clara
  • Menéndez, Pablo
The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell omics to interrogate cellular dynamics of non-transduced (CARneg) and transduced (CARpos) T cells, in the infusion product (IP) and at the CAR-T cell expansion peak in five B cell acute lymphoblastic leukemia (B-ALL) patients treated with CD19CAR-T cells (varni-cel). We identify significant differences in cellular dynamics in response to therapy. CARpos T cells at IP of complete response patients exhibit a significantly higher CD4:CD8 ratio, validated in a larger cohort B-ALL patients (n = 47). Conversely, at the expansion peak, there is a clonal expansion of CD8+ effector memory and cytotoxic T cells. Cytotoxic CARpos γδ-T cells expansion correlates with treatment efficacy validated in a cohort of B-ALL (n = 18) and diffuse large B cell lymphoma (DLBCL) patients (n = 58). Our data provide insights into the complexity of T cell responses following CAR-T cell therapy and suggest drivers of immunotherapy response., Research in P.M./C.B. laboratory was supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665), H2020 (101057250-CANCERNA), the Fight Kids Cancer Foundation (Cure2MLL project), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/10.13039/501100011033; FEDER Funds; CPP2021-008508, CPP2021-008676, and CPP2022-009759 funded by MICIU/AEI/10.13039/501100011033; and the European Union NextGenerationEU/PRTR), Ayudas Merck de Investigación from Health Merck Foundation, the Spanish Association Against Cancer (AECC, PRYGN234975MENE), and the ISCIII-RICORS within the Next Generation EU program (Plan de Recuperación, Transformación y Resilencia). Additional funding was provided to C.B. by AECC (PRYGN211192BUEN), the Uno Entre Cien Mil Foundation, AIE (MINECO PLE2021-007518), Deutsche José Carreras Leukämie-Stiftung (DJCLS/02R/2023), and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822 and PI24/00763)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7;12) (q36;p13) infant AML

  • Bousquets-Muñoz, Pablo
  • Molina, Oscar
  • Varela, Ignacio
  • Álvarez-Eguiluz, Ángel
  • Gómez Peris, Ana
  • Sánchez, Elena G.
  • Balbín, Milagros
  • Ruano, David
  • Ramírez-Orellana, Manuel
  • Puente, Xose S.
  • Menéndez, Pablo
Acute leukemia is the most frequently diagnosed malignancy in childhood, with acute lymphoblastic leukemia (ALL) comprising approximately 80% of cases in children aged 0–18 years, and acute myeloid leukemia (AML) accounting for approximately 15–20% [1]. The early onset (0–10 years) of most childhood acute leukemias and the high concordance rate among monozygotic twins suggest a prenatal origin of the disease [1]. Indeed, the presence of preleukemic precursors in cord blood (CB) samples or Guthrie blood spots from children who later developed acute leukemia has been demonstrated in several studies [2, 3]. However, this has mainly been demonstrated experimentally for the most common cytogenetic subtypes, particularly in ALL., This research was partially supported by a donation from the patient’s family and Heroga Fertilizantes. Research in PM’s laboratory is supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665), the H2020 EU program (101057250-CANCERNA), the MINECO (PID2022-142966OB-I00/ MCIN/AEI/10.13039/501100011033 and Feder Funds), the MINECO/European Union NextGenerationEU (CPP2021-008508, CPP2022-009759); the Deutsche José Carreras Leukämie-Stiftung (DJCLS15R/2021 and DJCLS 02R/2023), the Spanish Association Against Cancer (AECC, PRYGN234975MENE) and the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia). Research in XSP’s laboratory is supported by Ministerio de Ciencia e Innovación (PID2020-117185RB-I00); the Spanish Association Against Cancer (AECC); Centro de Investigación Biomédica en Red Cáncer (CIBERONC); “La Caixa” Foundation CLLSYSTEMS (HR22-00172), European Union NextGenerationEU/Mecanismo para la Recuperación y la Resilencia (MRR)/PRTR and the Instituto de Salud Carlos III (ISCIII) (PMP21/00015). OM and TV-H were supported by an investigator award from AECC (INVES211226MOLI and INVES223069VELA, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression

  • Arroyo-Ródenas, Javier
  • Falgàs, Aïda
  • Díez-Alonso, Laura
  • Martínez-Moreno, Alba
  • Roca-Ho, Heleia
  • Gil-Etayo, Francisco J.
  • Pérez-Pons, Alba
  • Aguilar-Sopeña, Óscar
  • Velasco-Sidro, Miriam
  • Gómez-Rosel, Marina
  • Jiménez-Matías, Beatriz
  • Muñoz-Sánchez, Guillermo
  • Pacheco, Yedra
  • Bravo-Martín, Clara
  • Ramírez-Fernández, Ángel
  • Jiménez-Reinoso, Anaïs
  • González-Navarro, Azucena
  • Juan, Manel
  • Orfao, Alberto
  • Blanco, Belén
  • Roda-Navarro, Pedro
  • Bueno, Clara
  • Menéndez, Pablo
  • Álvarez-Vallina, Luis
[Background] CD19-directed cancer immunotherapies, based on engineered T cells bearing chimeric antigen receptors (CARs, CAR-T cells) or the systemic administration of bispecific T cell-engaging (TCE) antibodies, have shown impressive clinical responses in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, more than half of patients relapse after CAR-T or TCE therapy, with antigen escape or lineage switching accounting for one-third of disease recurrences. To minimize tumor escape, dual-targeting CAR-T cell therapies simultaneously targeting CD19 and CD22 have been developed and validated both preclinically and clinically., [Methods] We have generated the first dual-targeting strategy for B-cell malignancies based on CD22 CAR-T cells secreting an anti-CD19 TCE antibody (CAR-STAb-T) and conducted a comprehensive preclinical characterization comparing its therapeutic potential in B-ALL with that of previously validated dual-targeting CD19/CD22 tandem CAR cells (TanCAR-T cells) and co-administration of two single-targeting CD19 and CD22 CAR-T cells (pooled CAR-T cells)., [Results] We demonstrate that CAR-STAb-T cells efficiently redirect bystander T cells, resulting in higher cytotoxicity of B-ALL cells than dual-targeting CAR-T cells at limiting effector:target ratios. Furthermore, when antigen loss was replicated in a heterogeneous B-ALL cell model, CAR-STAb T cells induced more potent and effective cytotoxic responses than dual-targeting CAR-T cells in both short- and long-term co-culture assays, reducing the risk of CD19-positive leukemia escape. In vivo, CAR-STAb-T cells also controlled leukemia progression more efficiently than dual-targeting CAR-T cells in patient-derived xenograft mouse models under T cell-limiting conditions., [Conclusions] CD22 CAR-T cells secreting CD19 T-cell engagers show an enhanced control of B-ALL progression compared with CD19/CD22 dual CAR-based therapies, supporting their potential for clinical testing., Research in LA-V laboratory is funded by the MCIN/AEI/10.13039/501100011033 (PID2023-148429OB-I00, PID2020-117323RB-I00, PDC2021-121711-I00, CPP2022-009762, CPP2022-009765, CPP2023-010827), the Carlos III (ISCIII) Health Institute with European Regional Development Fund (FEDER) cofinancing (DTS20/00089, PMPTA22/00167); the Asociación Española contra el Cáncer (AECC) (PROYE19084ALVA and PRYGN234844ALVA), the CRIS Cancer Foundation (FCRIS-2021-0090 and FCRIS-2023-0070), the Fundación ‘‘La Caixa’’ (HR21-00761 project IL7R_LungCan), the Fundación para la Investigación Biomédica del Hospital 12 de Octubre (programa Investiga 2022-0082), the Comunidad de Madrid (P2022/BMD-7225 Next Generation CART MAD), and the Fundación FERO (BBASELGAFERO2024.01). Research in PM/CB laboratory is supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support; “the European Research Council grants (ERC-PoC-957466 IT4B-TALL, ERC-PoC-101100665 BiTE-CAR); H2020 (101057250-CANCERNA), the MCIN/AEI/10.13039/501100011033 (PID2022-142966OB-I00 and Feder Funds), MCIN/European Union NextGeneration EU (CPP2021-008508 and CPP2022-009759); the AECC (PRYGN234975MENE and PRYGN211192BUEN), the Fundación Unoentrecienmil (FUECM2024), the ISCIII/FEDER (PI20/00822, PI24/00763) and the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia). BB is supported by the ISCIII (PI23/01256), AECC (INNOV211832BLAN) and Comunidad de Madrid (IND2022/BMD-23732). PR-N is funded by MCIN/AEI/10.13039/501100011033 (PID2020-115444GB-I00). AF was supported by a Juan de la Cierva fellowship from the Ministerio de Ciencia, Innovación y Universidades. LDA was supported by a Rio Hortega fellowship from the ISCIII (CM20/00004). OA-S was supported by a PhD fellowship from the Complutense University of Madrid. MG-R is supported by an Industrial PhD fellowship from Comunidad de Madrid (IND2022/BMD-23732)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia

  • Tirado, Néstor
  • Fidyt, Klaudyna
  • Mansilla, María José
  • Garcia-Perez, Alba
  • Martínez-Moreno, Alba
  • Vinyoles, Meritxell
  • Alcain, Juan
  • García-Peydró, Marina
  • Roca-Ho, Heleia
  • Fernandez-Fuentes, Narcis
  • Guerrero-Murillo, Mercedes
  • Falgàs, Aïda
  • Velasco-Hernandez, Talia
  • Bueno, Clara
  • Panelli, Patrizio
  • Mulens-Arias, Vladimir
  • Apostolov, Apostol
  • Engel, Pablo
  • González, Europa Azucena
  • Vick, Binje
  • Jeremias, Irmela
  • Caye-Eude, Aurélie
  • Baruchel, André
  • Cavé, Hélène
  • Genescà, Eulàlia
  • Ribera, Jordi
  • Díaz-Beyá, Marina
  • Martínez-Sánchez, María Victoria
  • Fuster, José Luis
  • Escudero López, Adela
  • Minguillón, Jordi
  • Pérez-Martínez, Antonio
  • Ramírez-Orellana, Manuel
  • Torrebadell, Montserrat
  • Díaz, Víctor M.
  • Toribio, María L.
  • Sánchez-Martínez, Diego
  • Menéndez, Pablo
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy characterized by high rates of induction failure and relapse, and effective targeted immunotherapies are lacking. Despite promising clinical progress with genome-edited CD7-directed CAR-T cells, which present significant logistical and regulatory issues, CAR-T cell therapy in T-ALL remains challenging due to the shared antigen expression between malignant and healthy T cells. This can result in CAR-T cell fratricide, T cell aplasia, and the potential for blast contamination during CAR-T cell manufacturing. Recently described CAR-T cells target non-pan-T antigens, absent on healthy T cells but expressed on specific T-ALL subsets. These antigens include CD1a (NCT05679895), which is expressed in cortical T-ALL, and CCR9. We show that CCR9 is expressed on >70% of T-ALL patients (132/180) and is maintained at relapse, with a safe expression profile in healthy hematopoietic and non-hematopoietic tissues. Further analyses showed that dual targeting of CCR9 and CD1a could benefit T-ALL patients with a greater blast coverage than single CAR-T cell treatments. We therefore developed, characterized, and preclinically validated a novel humanized CCR9-specific CAR with robust and specific antileukemic activity as a monotherapy in vitro and in vivo against cell lines, primary T-ALL samples, and patient-derived xenografts. Importantly, CCR9/CD1a dual-targeting CAR-T cells showed higher efficacy than single-targeting CAR-T cells, particularly in T-ALL cases with phenotypically heterogeneous leukemic populations. Dual CD1a/CCR9 CAR-T therapy may prevent T cell aplasia and obviate the need for allogeneic transplantation and regulatory-challenging genome engineering approaches in T-ALL., Research in PM laboratory is supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466 IT4B-TALL, ERC-PoC-101100665 BiTE-CAR); H2020 (101057250-CANCERNA), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/10.13039/501100011033 https://doi.org/10.13039/501100011033 and FEDER Funds, and CPP2021-008508, CPP2021-008676, CPP2022-009759 funded by MICIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR); “Ayudas Merck de Investigación” from Health Merck Foundation, and grant PID2022-136554OA-I00 funded by MICIU/AEI/10.13039/501100011033 https://doi.org/10.13039/501100011033 and the European Regional Development Fund (ERDF)/EU to DS-M; the AEI grant PID2022-138880OB-I00 to MLT, the Spanish Association Against Cancer (AECC, PRYGN234975MENE, PRYGN211192BUEN), the Uno Entre Cien Mil Foundation to MLT and to CB, and the Instituto de Salud Carlos III (ISCIII) through the Spanish Network of Advanced Therapies (RICORS/TERAV+), projects RD24/0014/0015, RD24/0014/0024 and RD24/0014/0042 and co-funded by the European Union (EU). AF was supported by a Juan de la Cierva postdoctoral fellowship (FJC2021-046789-I), VMD by a Torres Quevedo contract (PTQ2020-011056), AG-P by an industrial PhD fellowship (DIN2022-012556) and NT by a PhD fellowship (FPU19/00039) from the Spanish Ministry of Science and Innovation. KF is supported by the European Union’s Marie Skłodowska-Curie Actions (MSCA) Postdoctoral Fellowship (101153028). MVM-S is supported by the Asociación Pablo Ugarte (APU).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A human genome editing–based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features

  • Bueno, Clara
  • Torres-Ruiz, Raúl
  • Petazzi, Paolo
  • Vinyoles, Meritxell
  • Rodríguez-Perales, Sandra
  • Marschalek, Rolf
  • Fraga, Mario F.
  • Menéndez, Pablo
Letter to Blood: et al., Cellular ontogeny and MLL breakpoint site influence the capacity of MLL-edited CD34+ hematopoietic cells to initiate and recapitulate infant patients' features in pro–B-cell acute lymphoblastic leukemia (B-ALL). We provide key insights into the leukemogenic determinants of MLL-AF4+ infant B-ALL., Financial support for this work was obtained from the Spanish Ministry of Economy and Competitiveness (PID2022-142966OB-100ID2019), Heroes hasta la médula initiative and Instituto de Salud Carlos III (ISCIII)–Redes de Investigación Cooperativa Orientadas a Resultados en Salud within the Next Generation EU program (plan de recuperación, transformación y resiliencia) (P.M.) and the Health Institute Carlos III (ISCIII/Federacion Española de Enfermedades Raras) PI20/00822 (C.B.), PI20/01837 (S.R.-P.) and PI21/01641 (R.T.-R.). Asociación Española Contra el Cancer (PRYGN211192BUEN) (C.B.), AECC-LABAE20049RODR (S.R.-P.), and the Fundación Uno entre Cienmil (C.B.). R.T.-R. and O.M. were supported by investigator fellowships from the Spanish Association of Cancer Research (INVES211226MOLI). R.M. is supported by grants from the Deutsche Forschungsgemeinschaft (Ma 1876/12-1) and Wilhelm Sander foundation (2018.070.2)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness

  • Romero-Moya, Damià
  • Torralba-Sales, Eric
  • Calvo, Cristina
  • Marin-Bejar, Oskar
  • Magallon-Mosella, Maria
  • Distefano, Maximiliano
  • Pera, Joan
  • Castaño, Julio
  • Giorgio, Francesca De
  • González, Jessica
  • Iglesias, Arnau
  • Berenguer Balaguer, Clara
  • Schilling, Marcel
  • Plass, Mireya
  • Pasquali, Lorenzo
  • Català, Albert
  • Molina, Oscar
  • Wlodarski, Marcin W.
  • Bigas Salvans, Anna
  • Giorgetti, Alessandra
GATA2 deficiency is a monogenic transcriptopathy disorder characterized by bone marrow failure (BMF), immunodeficiency, and a high risk of developing myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). Although informative mouse models have been developed, the mechanisms by which GATA2 haploinsufficiency drives disease initiation in humans remain incompletely understood. To address this, we developed a novel humanized model using CRISPR/Cas9 technology to knock-in GATA2-R398W variant in primary cord blood CD34+ cells. Additionally, we introduced specific mutations in SETBP1 and ASXL1 to model distinct premalignant stages of GATA2 deficiency. Through clonal competition and serial transplantation assays, we demonstrated that human CD34 cells harboring the GATA2 mutation exhibit significantly reduced fitness in vivo when competing with wild-type cells. Notably, this fitness disadvantage persists even when GATA2 mutations are combined with oncogenic SETBP1 and ASXL1 drivers, underscoring the dominant, deleterious effect of GATA2 deficiency on hematopoietic stem cell function. Functional in vitro analyses revealed that GATA2-R398W mutation impairs cell proliferation, disrupts cell cycle progression, and induces mitotic defects, which may contribute to hematopoietic stem/progenitor cell loss and impaired self-renewal. Transcriptomic profiles of GATA2-mutant cells revealed that these functional defects are associated with reduced HSC self-renewal capacity and upregulation of the pre-aging phenotype. Our work highlights the feasibility of generating a human GATA2 deficiency model suitable for studying the biological consequences of various GATA2 variants and the generation of a platform to test potential phenotype-rescuing therapeutics., This work was supported by ERA PerMed GATA2-HuMo Funding Mechanism (Spain: Acció Instrumental de SLT011/18/00006 of the Department of Health of the Government of Catalonia), Ministerio de Ciencia e Innovación, which is part of Agencia Estatal de Investigación (AEI), through the Retos Investigación grant, number PID2020-115591RB-I00/ https://doi.org/10.13039/501100011033, and PID2023-146290OB-I00, Fundació La Marató TV3 228/C/2020, Award no. AC23_2/00040 by ISCIII through AES 2023 and within the European Joint Programme Rare Diseases framework, Instituto de Salud Carlos III (ISCIII), "Programa FORTALECE del Ministerio de Ciencia e Innovación", through the project number FORT23/00032 and Finançat per el Departament de Recerca i Universitats de la Generalitat de Catalunya i l'AGAUR (expedient 2021 SGR 00888) to AG. Funding for this project was provided in part by an EHA Research Grant award granted by the European Hematology Association (KOG-202109-01162) and the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 101029927 to OM-B. DR-M was supported by Deutsche José Carreras Leukämie-Stiftung, DJCLS 13 R/2022. JP and MD were supported by Fundació La Marató TV3 228/C/2020. MM-M was supported by the TC030-AND/2022 Predoctoral grant from the Government of Andorra. OM-B is currently supported by the Ramón y Cajal contract (RYC2021-032129-I) funded by AEI/European Social Fund UE. The work in the LP laboratory was supported by "la Caixa" Foundation, LCF-PR-HR24-00150 and by PID2023-151556OB-I00 and CNS2024-154742 funded by MICIU/AEI/10.13039/501100011033 and, as appropriate, by "ESF Investing in your future", by "ESF+" or by "European Union NextGenerationEU/PRTR". The work in AB laboratory was funded by ERA PerMed-Departament de Salut, Generalitat de Catalunya (SLT011/18/00007) and the EJP RD-Instituto de Salud Carlos III (AC23_2/00014). The work of CC and OM was supported by the Spanish Ministry of Economy and Competitiveness/European Union NextGenerationEU (PID2022-142966OB-I00) and the Deutsche José Carreras Leukämie-Stiftung (DJCLS 15 R/2023) to OM. CC is supported by a predoctoral fellowship from the Spanish Ministry of Economy and Competitiveness (PID2022-142966OB-I00). The work of MP was supported by a Ramón y Cajal contract of the Spanish Ministry of Science, Innovation and Universities (Grant: RYC2018-024564-I funded by MICIU/AEI/10.13039/501100011033 and by "El FSE invierte en tu futuro"). The work in the MP laboratory was supported by the project PID2022-139580OB-I00 funded by MICIU/AEI/10.13039/501100011033 and FEDER and by "ERDF A way of making Europe", by the European Union. MWW was supported by Evans MDS DRG grant and American Society of Hematology bridge award. Authors thank the members of the Advanced Optical Microscopy facility from UB (Scientific and Technological Centers, Universitat de Barcelona [CCiTUB]) for their technical support. We thank the CERCA Programme/Generalitat de Catalunya for institutional support.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

  • Guerrero Murillo, Mercedes
  • Marchese, Domenica, 1986-
  • Heyn, Holger
  • Menéndez, Pablo
The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell omics to interrogate cellular dynamics of non-transduced (CARneg) and transduced (CARpos) T cells, in the infusion product (IP) and at the CAR-T cell expansion peak in five B cell acute lymphoblastic leukemia (B-ALL) patients treated with CD19CAR-T cells (varni-cel). We identify significant differences in cellular dynamics in response to therapy. CARpos T cells at IP of complete response patients exhibit a significantly higher CD4:CD8 ratio, validated in a larger cohort B-ALL patients (n = 47). Conversely, at the expansion peak, there is a clonal expansion of CD8+ effector memory and cytotoxic T cells. Cytotoxic CARpos γδ-T cells expansion correlates with treatment efficacy validated in a cohort of B-ALL (n = 18) and diffuse large B cell lymphoma (DLBCL) patients (n = 58). Our data provide insights into the complexity of T cell responses following CAR-T cell therapy and suggest drivers of immunotherapy response., Research in P.M./C.B. laboratory was supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665), H2020 (101057250-CANCERNA), the Fight Kids Cancer Foundation (Cure2MLL project), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/10.13039/501100011033; FEDER Funds; CPP2021-008508, CPP2021-008676, and CPP2022-009759 funded by MICIU/AEI/10.13039/501100011033; and the European Union NextGenerationEU/PRTR), Ayudas Merck de Investigación from Health Merck Foundation, the Spanish Association Against Cancer (AECC, PRYGN234975MENE), and the ISCIII-RICORS within the Next Generation EU program (Plan de Recuperación, Transformación y Resilencia). Additional funding was provided to C.B. by AECC (PRYGN211192BUEN), the Uno Entre Cien Mil Foundation, AIE (MINECO PLE2021-007518), Deutsche José Carreras Leukämie-Stiftung (DJCLS/02R/2023), and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822 and PI24/00763).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression

  • Molina, Oscar|||0000-0001-7585-4519
  • Ortega-Sabater, C.
  • Thampi, Namitha|||0000-0001-6166-583X
  • Fernández Fuentes, Narcís|||0000-0002-6421-1080
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Martínez Moreno, Alba|||0000-0001-7514-260X
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Bueno, Clara|||0000-0003-1442-6216
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Granada, Isabel|||0000-0002-4275-0104
  • Campos, Diana
  • Giménez, Carles
  • Boer, Judith M.|||0000-0003-4848-7789
  • den Boer, Monique L.
  • Calvo, Gabriel F.|||0000-0002-3623-236X
  • Camós, Mireia|||0000-0003-3658-7942
  • Fuster, José Luis|||0000-0002-4881-9440
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Ballerini, Paola
  • Locatelli, Franco|||0000-0002-7976-3654
  • Mullighan, Charles G.|||0000-0002-1871-1850
  • Spierings, Diana C.J.|||0000-0001-8403-474X
  • Foijer, Floris|||0000-0003-0989-3127
  • Pérez-García, Víctor M.|||0000-0002-6575-495X
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Chromosomal instability (CIN) lies at the core of cancer development leading to aneuploidy, chromosomal copy-number heterogeneity (chr-CNH) and ultimately, unfavorable clinical outcomes. Despite its ubiquity in cancer, the presence of CIN in childhood B-cell acute lymphoblastic leukemia (cB-ALL), the most frequent pediatric cancer showing high frequencies of aneuploidy, remains unknown. Here, we elucidate the presence of CIN in aneuploid cB-ALL subtypes using single-cell whole-genome sequencing of primary cB-ALL samples and by generating and functionally characterizing patient-derived xenograft models (cB-ALL-PDX). We report higher rates of CIN across aneuploid than in euploid cB-ALL that strongly correlate with intraclonal chr-CNH and overall survival in mice. This association was further supported by in silico mathematical modeling. Moreover, mass-spectrometry analyses of cB-ALL-PDX revealed a "CIN signature" enriched in mitotic-spindle regulatory pathways, which was confirmed by RNA-sequencing of a large cohort of cB-ALL samples. The link between the presence of CIN in aneuploid cB-ALL and disease progression opens new possibilities for patient stratification and offers a promising new avenue as a therapeutic target in cB-ALL treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7, 12) (q36, p13) infant AML